{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:03:01Z","timestamp":1791849781010,"version":"4.3.4"},"reference-count":32,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,8,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A recent preclinical study suggested that imatinib may be cardiotoxic in some patients. We reviewed all reported serious adverse events of cardiac adverse events occurring in patients on clinical trials involving imatinib. Among 1276 patients enrolled, 22 (1.7%) were identified as having symptoms that could be attributed to systolic heart failure. The median age was 70 years (range, 49 to 83 years). The median time from start of imatinib therapy was 162 days (range, 2-2045 days). At the time these events were reported, 8 (0.6%) were considered possibly or probably related to imatinib. A total of 18 patients had previous medical conditions predisposing to cardiac failure: congestive heart failure (CHF; 6 [27%] patients), diabetes mellitus (6 [27%] patients), hypertension (10 [45%] patients), coronary artery disease (CAD; 8 [36%] patients), arrhythmia (3 [14%] patients), and cardiomyopathy (1 [5%] patient). Of the 22 patients, 11 continued imatinib therapy with dose adjustments and management for the CHF symptoms without further complications. Imatinib therapy as a causal factor of CHF is uncommon, mainly seen in elderly patients with preexisting cardiac conditions. Patients with previous cardiac history should be monitored closely and treated aggressively with standard medical therapy, including diuretics, if they develop symptoms suggestive of heart failure.<\/jats:p>","DOI":"10.1182\/blood-2007-01-070144","type":"journal-article","created":{"date-parts":[[2007,4,21]],"date-time":"2007-04-21T01:06:34Z","timestamp":1177117594000},"page":"1233-1237","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":206,"title":["Congestive heart failure is a rare event in patients receiving imatinib therapy"],"prefix":"10.1182","volume":"110","author":[{"given":"Ehab","family":"Atallah","sequence":"first","affiliation":[{"name":"Department of Leukemia and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Bernard","family":"Durand","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The University of Texas, M. D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"Department of Leukemia and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[{"name":"Department of Leukemia and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111712532566600_B1","first-page":"139","article-title":"Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors.","volume":"295","author":"Buchdunger","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"2019111712532566600_B2","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1182\/blood-2003-01-0081","article-title":"Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome.","volume":"101","author":"Cortes","year":"2003","journal-title":"Blood"},{"key":"2019111712532566600_B3","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa020461","article-title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.","volume":"347","author":"Demetri","year":"2002","journal-title":"N Engl J Med"},{"key":"2019111712532566600_B4","doi-asserted-by":"crossref","first-page":"1089a","DOI":"10.1182\/blood.V106.11.1089.1089","article-title":"Five year follow-up results of a phase II trial in patients with late chronic phase (L-CP) chronic myeloid leukemia (CML) treated with imatinib who are refractory\/intolerant of interferon-{alpha} [abstract].","volume":"106","author":"Gambacorti","year":"2005","journal-title":"Blood"},{"key":"2019111712532566600_B5","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1182\/blood-2003-08-2958","article-title":"Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate.","volume":"103","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"2019111712532566600_B6","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.2005.03.2177","article-title":"High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group.","volume":"24","author":"Yanada","year":"2006","journal-title":"J Clin Oncol"},{"key":"2019111712532566600_B7","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"2019111712532566600_B8","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMc051946","article-title":"Imatinib for the treatment of pulmonary arterial hypertension.","volume":"353","author":"Ghofrani","year":"2005","journal-title":"N Engl J Med"},{"key":"2019111712532566600_B9","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1056\/NEJMc052500","article-title":"Imatinib and hyperlipidemia.","volume":"353","author":"Gottardi","year":"2005","journal-title":"N Engl J Med"},{"key":"2019111712532566600_B10","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1158\/1078-0432.12.11.1","article-title":"U.S Food and Drug Administration drug approval summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.","volume":"11","author":"Cohen","year":"2005","journal-title":"Clin Cancer Res"},{"key":"2019111712532566600_B11","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nm1446","article-title":"Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.","volume":"12","author":"Kerkela","year":"2006","journal-title":"Nat Med"},{"key":"2019111712532566600_B12","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/archinte.159.11.1197","article-title":"Profile for estimating risk of heart failure.","volume":"159","author":"Kannel","year":"1999","journal-title":"Arch Intern Med"},{"key":"2019111712532566600_B13","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11897-006-0026-6","article-title":"Recent insights into cardiac hypertrophy and left ventricular remodeling.","volume":"3","author":"Kerkela","year":"2006","journal-title":"Curr Heart Fail Rep"},{"key":"2019111712532566600_B14","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1161\/01.HYP.0000202487.68969.f7","article-title":"Imatinib attenuates end-organ damage in hypertensive homozygous TGR(mRen2)27 rats.","volume":"47","author":"Schellings","year":"2006","journal-title":"Hypertension"},{"key":"2019111712532566600_B15","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1161\/01.CIR.0000039105.49749.6F","article-title":"Lifetime risk for developing congestive heart failure: the Framingham heart study.","volume":"106","author":"Lloyd-Jones","year":"2002","journal-title":"Circulation"},{"key":"2019111712532566600_B16","first-page":"e85","article-title":"Heart disease and stroke statistics\u20142006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.","volume":"113","author":"Thom","year":"2006","journal-title":"Circulation"},{"key":"2019111712532566600_B17","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jama.1996.03530440037034","article-title":"The progression from hypertension to congestive heart failure.","volume":"275","author":"Levy","year":"1996","journal-title":"JAMA"},{"key":"2019111712532566600_B18","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.amjmed.2006.05.024","article-title":"Diabetes in heart failure: prevalence and impact on outcome in the population.","volume":"119","author":"From","year":"2006","journal-title":"Am J Med"},{"key":"2019111712532566600_B19","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/00042737-200603000-00010","article-title":"Fatal cardiomyopathy associated with pegylated interferon\/ribavirin in a patient with chronic hepatitis C.","volume":"18","author":"Condat","year":"2006","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2019111712532566600_B20","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.","volume":"353","author":"Harrison","year":"2005","journal-title":"N Engl J Med"},{"key":"2019111712532566600_B21","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1056\/NEJM199809243391307","article-title":"Doxorubicin-induced cardiomyopathy.","volume":"339","author":"Singal","year":"1998","journal-title":"N Engl J Med"},{"key":"2019111712532566600_B22","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N Engl J Med"},{"key":"2019111712532566600_B23","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","article-title":"Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase 2 study.","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood"},{"key":"2019111712532566600_B24","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","article-title":"Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.","volume":"99","author":"Talpaz","year":"2002","journal-title":"Blood"},{"key":"2019111712532566600_B25","doi-asserted-by":"crossref","first-page":"9359","DOI":"10.1200\/JCO.2005.03.2185","article-title":"Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.","volume":"23","author":"Reardon","year":"2005","journal-title":"J Clin Oncol"},{"key":"2019111712532566600_B26","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/blood-2001-12-0181","article-title":"A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome\u2013positive acute lymphoid leukemias.","volume":"100","author":"Ottmann","year":"2002","journal-title":"Blood"},{"key":"2019111712532566600_B27","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/cncr.21834","article-title":"Multicenter phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy.","volume":"106","author":"Wyman","year":"2006","journal-title":"Cancer"},{"key":"2019111712532566600_B28","doi-asserted-by":"crossref","first-page":"2136a","DOI":"10.1182\/blood.V108.11.2136.2136","article-title":"Declining rates of adverse events (AEs), rare occurrence of serious AEs (SAEs), and no unexpected long-term side effects at 5 years in patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CP) initially treated with imatinib (IM) in the International Randomized Study of Interferon vs STI571 (IRIS) [abstract].","volume":"108","author":"Kantarjian","year":"2006","journal-title":"Blood"},{"key":"2019111712532566600_B29","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nm0107-13a","article-title":"In reply to \u201cCardiotoxicity of the cancer therapeutic agent imatinib mesylate\u201d [letter].","volume":"13","author":"Hatfield","year":"2007","journal-title":"Nat Med"},{"key":"2019111712532566600_B30","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nm0107-15a","article-title":"In reply to \u201cCardiotoxicity of the cancer therapeutic agent imatinib mesylate\u201d [letter].","volume":"13","author":"Rosti","year":"2007","journal-title":"Nat Med"},{"key":"2019111712532566600_B31","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nm0107-13b","article-title":"In reply to \u201cCardiotoxicity of the cancer therapeutic agent imatinib mesylate\u201d [letter].","volume":"13","author":"Gambacorti","year":"2007","journal-title":"Nat Med"},{"key":"2019111712532566600_B32","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/nm0107-14","article-title":"In reply to \u201cCardiotoxicity of the cancer therapeutic agent imatinib mesylate\u201d [letter].","volume":"13","author":"Atallah","year":"2007","journal-title":"Nat Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/110\/4\/1233\/1480103\/zh801607001233.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/110\/4\/1233\/1480103\/zh801607001233.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T14:53:22Z","timestamp":1707836002000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/110\/4\/1233\/23171\/Congestive-heart-failure-is-a-rare-event-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,15]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,8,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2007-01-070144","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,15]]}}}